Cancer chemotherapy

Drug-Induced Liver Disease

Volumn , Issue , 2002, Pages 593-632

  DeLeve, Laurie D ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928863477     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (247)

1. Zimm S, Colins JM, O’Neill D, Chabner BA, Poplack DG. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 1983; 34:810-817.
2. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000; 60:1189-1192.
3. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101:847-854.
4. Sugiyama Y, Kato Y, Chu X. Multiplicity of biliary excretion mechanisms for the campto-thecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother Pharmacol 1998; 42(suppl):S44-S49.
5. Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, Pesheck CV, Lord RS, 3rd. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 2000; 28:423-433.
6. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998; 32:554-563.
7. Gupta E, Wang X, Ramirez J, Ratain MJ. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol 1997; 39:440-444.
8. Ren S, Yang JS, Kalhorn TF, Slattery JT. Oxidation of cyclophosphamide to 4-hydroxycyclo-phosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 1997; 57:4229-4235.
9. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39:361-398.
10. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995; 40:523-530.
11. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10:1635-1642.
12. Ellis AG, Webster LK. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. Cancer Chemother Pharmacol 1999; 43:13-18.
13. Ellis AG, Crinis NA, Webster LK. Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother Pharmacol 1996; 38:8187.
14. Yule SM, Walker D, Cole M, McSorley L, Cholerton S, Daly AK, Pearson AD, Boddy AV. The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metab Dispos 1999; 27:417-421.
15. Villikka K, Kivisto KT, Maenpaa H, Joensuu H, Neuvonen PJ. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 1999; 66:589-593.
16. Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996; 56:58-65.
17. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999; 17:1516-1525.
18. Larroquette CA, Hortobagyi GN, Buzdar AU, Holmes FA. Subclinical hepatic toxicity during combination chemotherapy for breast cancer. JAMA 1986; 256:2988.
19. Zhou-Pan XR, Seree E, Zhou XJ, Placidi M, Maurel P, Barra Y, Rahmani R. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993; 53:5121-5126.
20. Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation: metabolic drug interactions. Biochem Pharmacol 1993; 45:853-861.
21. Kajita J, Kuwabara T, Kobayashi H, Kobayashi S. CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 2000; 28:1121-1127.
22. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6 alphahydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994; 54: 5543-5546.
23. Robieux I, Sorio R, Borsatti E, Cannizzaro R, Vitali V, Aita P, Freschi A, Galligioni E, Monfardini S. Pharmacokinetics of vinorelbine in patients with liver metastasis. Clin Pharmacol Ther 1996; 59:32-40.
24. Figg WD, Dukes GE, Pritchard JF, Herman DJ, Lesesne HR, Carson SW, Songer SS, Powell JR, Hak LJ. Pharmacokinetics of ondansetron in patients with hepatic insufficiency. J Clin Pharmacol 1996; 36:206-215.
25. Locasciulli A, Testa M, Pontisso P, Benvegnu L, Fraschini D, Corbetta A, Noventa F, Masera G, Alberti A. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. Blood 1997; 90:4628-4633.
26. Farrow AC, Buchanan GR, Zwiener RJ, Bowman WP, Winick NJ. Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 1997; 15:1560-1566.
27. Meir H, Balawi I, Nayel H, El Karaksy H, El Haddad A. Hepatic dysfunction in children with acute lymphoblastic leukemia in remission: relation to hepatitis infection. Med Pediatr Oncol 2001; 36:469-473.
28. Horina JH, Wirnsberger GH, Kenner L, Holzer H, Krejs GJ. Increased susceptibility for CsA-induced hepatotoxicity in kidney graft recipients with chronic viral hepatitis C. Transplantation 1993; 56:1091-1094.
29. Zylberberg H, Carnot F, Mamzer M-F, Blancho G, Legendre C, Pol S. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation. Transplantation 1997; 63: 158-160.
30. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157:1871-1876.
31. Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG, Kim S, Flowers ME, McDonald GB. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999; 29:1893-1899.
32. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
33. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-562.
34. Cheng AL. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin’s lymphoma [letter]. Blood 1996; 87:1202.
35. Durnas C, Loi CM, Cusack BJ. Hepatic drug metabolism and aging. Clin Pharmacokinet 1990; 19:359-389.
36. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997; 61:331-339.
37. Le Couteur DG, Cogger VC, Markus AM, Harvey PJ, Yin ZL, Annselin AD, McLean AJ. Pseudocapillarization and associated energy limitation in the aged rat liver. Hepatology 2001; 33:537-543.
38. Etienne MC, Chatelut E, Pivot X, Lavit M, Pujol A, Canal P, Milano G. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion: a NONMEM analysis. Eur J Cancer 1998; 34:92-97.
39. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Cancer 1994; 75:11-17.
40. Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther 1995; 58:512-522.
41. den Hartigh J, McVie JG, van Oort WJ, Pinedo HM. Pharmacokinetics of mitomycin C in humans. Cancer Res 1983; 43:5017-5021.
42. Miya T, Sasaki Y, Karato A, Saijo N. Pharmacokinetic study of mitomycin C with emphasis on the influence of aging. Jpn J Cancer Res 1992; 83:1382-1385.
43. Wade JR, Kelman AW, Kerr DJ, Robert J, Whiting B. Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemother Pharmacol 1992; 29:391-395.
44. Cusack BJ, Mushlin PS, Johnson CJ, Vestal RE, Olson RD. Aging increases the cardiotoxic-ity of daunorubicin and daunorubicinol in the rat. J Gerontol. Series A, Biol Sci Med Sci 1996; 51:B376-B384.
45. Cusack BJ, Young SP, Vestal RE, Olson RD. Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat. Cancer Chemother Pharmacol 1997; 39:505-512.
46. Anonymous. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis: Rheumatoid Arthritis Clinical Trial Archive Group. J Rheumatol 1995; 22:218-223.
47. Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, Rubens RD. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 1995; 36:473-476.
48. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998; 25:72-85.
49. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Orav EJ, Gelber RD, Colan SD. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332:1738-1743.
50. Silber JH, Jakacki RI, Larsen RL, Goldwein JW, Barber G. Increased risk of cardiac dysfunction after anthracyclines in girls [see comments]. Med Pediatr Oncol 1993; 21:477-479.
51. Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number: Tomudex International Study Group. Eur J Cancer 1998; 34:1871-1875.
52. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renee N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999; 79: 627-630.
53. Bressolle F, Joulia JM, Pinguet F, Ychou M, Astre C, Duffour J, Gomeni R. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 1999; 44:295-302.
54. Chazal M, Etienne MC, Renee N, Bourgeon A, Richelme H, Milano G. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res 1996; 2:507-510.
55. Lu Z, Zhang R, Carpenter JT, Diasio RB. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 1998; 4:325-329.
56. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokin 1996; 31:47-64.
57. Davis LE, Lenkinski RE, Shinkwin MA, Kressel HY, Daly JM. The effect of dietary protein depletion on hepatic 5-fluorouracil metabolism. Cancer 1993; 72:3715-3722.
58. Cusack BJ, Young SP, Loseke VL, Hurty MR, Beals L, Olson RD. Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. Cancer Chemother Pharmacol 1992; 30: 145-148.
59. DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996; 24:830-837.
60. Wang X, Kanel GC, DeLeve LD. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat. Hepatology 2000; 31:428-434.
61. Geraci JP, Mariano MS, Jackson KL. Radiation hepatology of the rat: microvascular fibrosis and enhancement of liver dysfunction by diet and drugs. Radiat Res 1992; 129:322-332.
62. Iyer L, Ratain MJ. Pharmacogenetics and cancer chemotherapy. Eur J Cancer 1998; 34:1493-1499.
63. Bosma PJ, Roy Chowdhury J, Bakker C, Gantla S, De Boer A, Oostra BA, Lindhout D, Tytgat GNJ, Jansen PLM, Oude Elferink RPJ, Roy Chowdhury N. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase I in Gilbert’s syndrome. N Engl J Med 1998; 333:1171-1175.
64. Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M, Misset JL, Cvitkovic E. Severe CPT-11 toxicity in patients with Gilbert’s syndrome: two case reports. Ann Oncol 1997; 8:1049-1051.
65. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, Di Rienzo A, Ratain MJ. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucu-ronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999; 65:576-582.
66. Strasser SI, McDonald GB. Gastrointestinal and hepatic complications. In: ED Thomas, KG Blume, SJ Forman, eds. Hematopoietic Cell Transplantation. Cambridge, MA: Blackwell Scientific Publications, 1999:627-658.
67. Willmot FC, Robertson GW. Senecio disease, or cirrhosis of the liver due to senecio poisoning. Lancet 1920; 2:848-849.
68. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85:3005-3020.
69. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shul-man HM, Clift RA. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation—a cohort study of 355 patients. Ann Intern Med 1993; 118:255-267.
70. Jones RJ, Lee KSK, Beschorner WE, Vogel VG, Grochow LB, Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44:778-783.
71. Blostein MD, Paltiel OB, Thibault A, Rybka WB. A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation. Bone Marrow Transplant. 1992; 10:439-443.
72. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Venoocclu-sive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11:1729-1736.
73. Hommeyer SC, Teefey SA, Jacobson AF, Higano CS, Bianco JA, Colacurcio CJ, McDonald GB. Venoocclusive disease of the liver: Prospective study of US evaluation. Radiology 1992; 683:686.
74. Teefey SA, Brink JA, Borson RA, Middleton WD. Diagnosis of venoocclusive disease of the liver after bone marrow transplantation: value of duplex sonography. AJR 1995; 164: 1397-1401.
75. Deeg HJ, Shulman HM, Schmidt E, Yee GC, Thomas ED, Storb R. Marrow graft rejection and veno-occlusive disease of the liver in patients with aplastic anemia conditioned with cyclophosphamide and cyclosporine. Transplantation 1986; 42:497-501.
76. Peters WP, Henner WD, Grochow LB, Olsen G, Edwards S, Stanbuck H, Stuart A, Gocker-man J, Moore J, Bast RC, Jr., Seigler HF, Colvin OM. Clinical and pharmacological effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 1987; 47:6402-6406.
77. Ayash LJ, Elias A, Wheeler C, Reich E, Schwartz G, Mazanet R, Tepler I, Warren D, Lynch C, Gonin R, Schnipper L, Frei E, III, Antman K. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12:37-44.
78. Singhal S, Powles R, Treleaven J, Horton C, Swansbury GJ, Mehta J. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women. Bone Marrow Transplant 1996; 18:1049-1055.
79. Moreau P, Fiere D, Bezwoda WR, Facon R, Attal M, Laporte JP, Colombat P, Haak HL, Monconduit M, Lockhorst H, Girault D, Harousseau JL. Prospective randomized placebocontrolled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma. J Clin Oncol 1997; 15:660-666.
80. Fajardo LF, Berthrong M. Radiation injury in surgical pathology. Am J Surg 1978; 2:159-199.
81. Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 1999; 5:306-315.
82. Srivastava A, Bradstock KF, Szer J, de Bortoli L, Gottlieb DJ. Busulphan and melphalan prior to autologous bone marrow transplantation. Bone Marrow Transplant 1993; 12:323-329.
83. DeLeve LD, Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology 2000; 60:143-154.
84. Meresse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet D, Brugieres L, Lemerle J. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992; 10:135-141.
85. Vahrmeijer AL, van Dierendonck JH, Schutrups J, van de Velde CJ, Mulder GJ. Effect of glutathione depletion on inhibition of cell cycle progression and induction of apoptosis by melphalan (L-phenylalanine mustard) in human colorectal cancer cells. Biochem Pharmacol 1999; 58:655-664.
86. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 2000; 39:155-165.
87. McDonald GB, Ren S, Bouvier ME, Risler L, Kalhorn TF, Cole SL, Gooley TA, Schoch HG, Batchelder AL, McDonald SJ, Linterman R, Ellis S, Slattery JT. Venoocclusive disease of the liver and cyclophosphamide pharmacokinetics: a prospective study in marrow transplant patients. Hepatology 1999; 30:314A.
88. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR, Mylotarg Study G. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19:3244-3254.
89. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92:406-413.
90. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction following Gemtuzumab ozogamicin (Mylotarg). Blood 2002; 2310-2314.
91. Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB. Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994; 19:1171-1180.
92. Rollins BJ. Hepatic veno-occlusive disease. Am J Med 1986; 81:297-306.
93. DeLeve LD. Dacarbazine toxicity in murine liver cells: a novel model of hepatic endothelial injury and glutathione defense. J Pharmacol Exp Ther 1994; 268:1261-1270.
94. DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N. Toxicity of azathioprine and mono-crotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology 1996; 23:589-599.
95. DeLeve LD, McCuskey RS, Wang X, Hu L, McCuskey MK, Epstein RB, Kanel G. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 1999; 29:1779-1791.
96. DeLeve LD, Ito Y, Machen NW, McCuskey MK, Wang X, McCuskey RS. Embolization by sinusoidal lining cells causes the congestion of hepatic venoocclusive disease. Gastroenterology 2000; 118:A2345.
97. DeLeve LD, Wang X, Tsai J, Kanel G, Tokes Z. Prevention of hepatic venooclusive disease in the rat by inhibition of matrix metalloproteinases. Gastroenterology 2001; 120:A54.
98. Cai T, Fassina GF, Morini M, Aluigi MG, Masiello L, Fontanini G, D’Agostini F, De Flora S, Noonan DM, Albini A. A-Acetylcysteine inhibits endothelial cell invasion and angiogenesis. Lab Invest 1999; 79:1151-1159.
99. Tyagi SC, Ratajska A, Weber KT. Myocardial matrix metalloproteinase(s): localization and activation. Mol Cell Biochem 1993; 126:49-59.
100. Tyagi SC, Kumar S, Borders S. Reduction-oxidation (redox) state regulation of extracellular matrix metalloproteinases and tissue inhibitors in cardiac normal and transformed fibroblast cells. J Cell Biochem 1996; 61:139-151.
101. Upadhya GA, Strasberg SM. Glutathione, lactobionate, and histidine: cryptic inhibitors of matrix metalloproteinases contained in University of Wisconsin and histidine/tryptophan/ketoglutarate liver preservation solutions. Hepatology 2000; 31:1115-1122.
102. DeLeve LD, Wang X. Decrease in nitric oxide production contributes to hepatic venoocclu-sive disease. Hepatology 1999; 30:218A.
103. Eberhardt W, Beeg T, Beck KF, Walpen S, Gauer S, Bohles H, Pfeilschifter J. Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells. Kidney Int 2000; 57:59-69.
104. Korte W. Veno-occlusive disease of the liver after bone marrow transplantation: is hypercoagulability really part of the problem? Blood Coagul Fibrinol 1997; 8:367-381.
105. Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation-immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987; 127:549-558.
106. Brooks SEH, Miller CG, McKenzie K, Audretsch JJ, Bras G. Acute veno-occlusive disease of the liver. Arch Pathol 1970; 89:507-520.
107. Snover DC, Weisdorf S, Bloomer J, McGlave P, Weisdorf D. Nodular regenerative hyperplasia of the liver following bone marrow transplantation. Hepatology 1989; 9:443-448.
108. Wanless IR, Godwin TA, Allen F, Feder A. Nodular regenerative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy. A morphometric study of nine cases with an hypothesis on the pathogenesis. Medicine 1980; 59:367-379.
109. Thomas PA, McCusker JJ, Merrigan EH, Conte NF. Lobar cirrhosis with nodular hyperplasia (hamartoma) of the liver treated by left hepatic lobectomy. Am J Surg 1966; 112:831-834.
110. Whelan TJ, Baugh JH, Chandor S. Focal nodular hyperplasia of the liver. Ann Surg 1973; 177:150-158.
111. Travers H, D’Amato NA. Vascular alterations in focal nodular hyperplasia of the liver. Milit Med 1978; 143:96-101.
112. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990; 11:787-797.
113. Haboubi NY, Ali HH, Whitwell HL, Ackrill P. Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations. Am J Gastroenterol 1988; 83:256-261.
114. Bohme M, Muller M, Leier I, Jedlitschky G, Keppler D. Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. Gastroenterology 1994; 107:255-265.
115. Kadmon M, Klünemann C, Böhme M, Ishikawa T, Gorgas K, Otto G, Herfarth C, Keppler D. Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepa-tocyte into bile. Gastroenterology 1993; 104:1507-1514.
116. Böhme M, Büchler M, Müller M, Keppler D. Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett 1993; 333:193-196.
117. Moran D, De Buitrago JM, Fernandez E, Galan AI, Munoz ME, Jimenez R. Inhibition of biliary glutathione secretion by cyclosporine A in the rat: Possible mechanisms and role in the cholestasis induced by the drug. J Hepatol 1998; 29:68-77.
118. Yasumiba S, Tazuma S, OchiH, Chayama K, KajiyamaG. Cyclosporin A reduces canalicular membrane fluidity and regulates transporter function in rats. Biochem J 2001; 354:591-596.
119. Azer SA, Stacey NH. Differential effects of cyclosporin A on the transport of bile acids by human hepatocytes. Biochem Pharmacol 1993; 46:813-819.
120. Mosely RH, Johnson TR, Morrissette JM. Inhibition of bile acid transport by cyclosporine A in rat liver plasma membrane vesicles. J Pharmacol Exp Ther 1990; 253:974-980.
121. Tamai I, Safa AR. Competitive inhibition of cyclosporins with the vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. J Biol Chem 1990; 265:16509-16513.
122. Roman ID, Monte MJ, Gonzalez-Buitrago JM, Esteller A, Jimenez R. Inhibition of hepato-cytary vesicular transport by cyclosporin A in the rat: relationship with cholestasis and hyperbilirubinemia. Hepatology 1990; 12:83-91.
123. Roman ID, Coleman R. Disruption of canalicular function in isolated rat hepatocyte couplets caused by cyclosporin A. Biochem Pharmacol 1994; 48:2181-2188.
124. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26:664-669.
125. Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46:1323-1330.
126. Mori T, Sugita K, Suzuki T, Ishikawa T, Kurosawa H, Matsui A. Histopathologic features of the biopsied liver at onset of childhood B-precursor acute lymphoblastic leukemia presenting as severe jaundice. J Pediatr Gastroenterol Nutr 1997; 25:354-357.
127. Modzelewski JR, Jr., Daeschner C, Joshi VV, Mullick FG, Ishak KG. Veno-occlusive disease of the liver induced by low-dose cyclophosphamide. Mod Pathol 1994; 7:967-972.
128. Patel JM, Block ER. Acrolein-induced injury to cultured pulmonary artery endothelial cells. Toxicol Appl Pharmacol 1993; 122:46-53.
129. Kachel DL, Martin WJ, II. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther 1994; 268:42-46.
130. Shepherd PC, Fooks J, Gray R, Allan NC. Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension. Results from MRC CML. II. Trial comparing busulphan with busulphan and thioguanine. Br J Haematol 1991; 79:185-192.
131. Shulman HM, McDonald GB, Matthews D, Doney KC, Kopecky KJ, Gauvreau JM, Thomas ED. An analysis of hepatic venoocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 1980; 79:1178-1191.
132. Kanfer EJ, Petersen FB, Buckner CD, Stewart P, Storb R, Hill RS, Appelbaum FR, Clift RA, Doney KC, Shulman HM, Thomas ED. Phase I study of high-dose dimethylbusulfan followed by autologous bone marrow transplantation in patients with advanced malignancy. Cancer Treat Rep 1987; 71:101-102.
133. Paschke R, Heine M. Pathophysiological aspects of dacarbazine-induced human liver damage. Hepatogastroenterology 1985; 32:273-275.
134. Hill DL. Microsomal metabolism of triazenylimidazoles. Cancer Res 1975; 35:3106-3110.
135. Lazarus HM, Herzig RH, Graham-Pole J, Wolff SN, Phillips GL, Strandjord S, Hurd D, Forman W, Gordon EM, Coccia P, Gross S, Herzig GP. Intensive melphalan chemotherapy and cryopreserve autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1983; 1:359-367.
136. Awasthi S, Bajpai KK, Piper JT, Singhal SS, Ballatore A, Seifert WE, Jr., Awasthi YC, Ansari GA. Interactions of melphalan with glutathione and the role of glutathione 5-transferase. Drug Metab Dispos 1996; 24:371-374.
137. Paumi CM, Ledford BG, Smitherman PK, Townsend AJ, Morrow CS. Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance: kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. J Biol Chem 2001; 276:7952-7956.
138. Hutter RVP, Shipkey FH, Tan CTC, Murphy ML, Chowdhury M. Hepatic fibrosis in children with acute leukemia: a complication of therapy. Cancer 1960; 13:288-307.
139. Weber BL, Tanyer G, Poplack DG, Reaman GH, Feusner JH, Miser JS, Bleyer WA. Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood. NCI Monogr 1987: 207-212.
140. Schmiegelow K, Pulczynska M. Prognostic significance of hepatotoxicity during maintenance chemotherapy for childhood acute lymphoblastic leukaemia. Br J Cancer 1990; 61: 767-772.
141. Rask C, Albertioni F, Bentzen SM, Schroeder H, Peterson C. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia—a logistic regression analysis. Acta Oncol 1998; 37:277-284.
142. Ruymann FB, Mosjczuk AD, Sayers RJ. Hepatoma in a child with methotrexate-induced hepatic fibrosis. JAMA 1977; 238:2631-2633.
143. Fried M, Kalra J, Ilardi CF, Sawitsky A. Hepatocellular carcinoma in a long-term survivor of acute lymphocytic leukemia. Cancer 1987; 60:2548-2552.
144. Whiting-O’Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta analysis. Am J Med 1991; 90:711-716.
145. Frei E, III, Holland JF, Schneiderman MA, Pinkel D, Selkirk G, Freireich EJ, Silver RT, Gold GL, Regelson W. A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood 1958; 13:1126-1148.
146. Farber S. Summary of experience with 6-mercaptopurine. Ann NY Acad Sci 1954; 60:412-414.
147. McIlvanie SK, MacCarthy JD. Hepatitis in association with prolonged 6-mercaptopurine therapy. Blood 1959; 14:80-90.
148. Einhorn M, Davidsohn I. Hepatotoxicity of mercaptopurine. JAMA 1964; 188:802-806.
149. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111:641-649.
150. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm Res 1999; 16:342-349.
151. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000; 14:567-572.
152. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus [see comments]. J Natl Cancer Inst 1999; 91:2001-2008.
153. Berkovitch M, Matsui D, Zipursky A, Blanchette VS, Verjee Z, Giesbrecht E, Saunders EF, Evans WE, Koren G. Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: Pharmacokinetic characteristics. Med Pediatr Oncol 1996; 26:85-89.
154. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG. Phar-macogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118:705-713.
155. Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, Relling MV. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001; 61:5810-5816.
156. Merino JM, Casanova F, Saez-Royuela F, Velasco A, Gonzalez JB. Veno-occlusive disease of the liver associated with thiopurines in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2000; 17:429-431.
157. Griner PF, Elbadawi A, Packman CH. Veno-occlusive disease of the liver after chemotherapy of acute leukemia: report of two cases. Ann Intern Med 1976; 85:578-582.
158. D’Cruz CA, Wimmer RS, Harcke HT, Huff DS, Naiman JL. Veno-occlusive disease of the liver in children following chemotherapy for acute myelocytic leukemia. Cancer 1983; 52: 1803-1807.
159. Satti MB, Weinbren K, Gordon-Smith EC. 6-Thioguanine as a cause of toxic veno-occlusive disease of the liver. J Clin Pathol 1982; 35:1086-1091.
160. Key NS, Kelly PM, Emerson PM, Chapman RW, Allan NC, McGee JO. Oesophageal varices associated with busulphan-thioguanine combination therapy for chronic myeloid leukaemia. Lancet 1987; 2:1050-1052.
161. Larrey D, Freneaux E, Berson A, Babany G, Degott C, Valla D, Pessayre D, Benhamou JP. Peliosis hepatis induced by 6-thioguanine administration. Gut 1988; 29:1265-1269.
162. de Araujo MS, Gerard F, Chossegros P, Porto LC, Barlet P, Grimaud JA. Vascular hepato-toxicity related to heroin addiction. Virchows Arch A Pathol Anat Histopathol 1990; 417: 497-503.
163. Trigueiro de Araujo MS, Gerard F, Chossegros P, Guerret S, Grimaud JA. Lack of hepatocyte involvement in the genesis of the sinusoidal dilatation related to heroin addiction: a morphometric study. Virchows Arch A Pathol Anat Histopathol 1992; 420:149-153.
164. Zafrani ES, Cazier A, Baudelot AM, Feldmann G. Ultrastructural lesions of the liver in human peliosis. A report of 12 cases. Am J Pathol 1984; 114:349-359.
165. DeLeve LD. Glutathione defense in non-parenchymal cells. Semin Liver Dis 1998; 18:403-413.
166. Porta C, Danova M, Accurso S, Tinelli C, Girino M, Riccardi A, Palmeri S. Sequential intrahepatic and systemic fluoropyrimidine-based chemotherapy for metastatic colorectal cancer confined to the liver: a phase II study. Cancer Chemother Pharmacol 2001; 47:423-428.
167. Kemeny N, Gonen M, Sullivan D, Schwartz L, Benedetti F, Saltz L, Stockman J, Fong Y, Jarnagin W, Bertino J, Tong W, Paty P. Phase I study of hepatic arterial infusion of floxuri-dine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001; 19:2687-2695.
168. Campos LT. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexa-methasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer [letter; comment]. Cancer 1993; 71:875-876.
169. Kemeny N, Seiter K, Niedzwiecki D, Chapman D, Sigurdson E, Cohen A, Botet J, Oderman P, Murray P. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexa-methasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992; 69:327-334.
170. Brown KT, Kemeny N, Berger MF, Getrajdman GI, Napp T, Fong Y, Herman S, Kurtz RC, Botet J, Blumgart LH. Obstructive jaundice in patients receiving hepatic artery infusional chemotherapy: etiology, treatment implications, and complications after transhepatic biliary drainage. J Vasc Interv Radiol 1997; 8:229-234.
171. Ludwig J, Kim CH, Wiesner RH, Krom RA. Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy? Hepatology 1989; 9:215-218.
172. Neumeister P, Eibl M, Zinke-Cerwenka W, Scarpatetti M, Sill H, Linkesch W. Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate. Ann Hematol 2001; 80:119-120.
173. Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, King DJ, Haines AM, Hamann P, Hinman L, Shochat D, Bernstein ID. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996; 56:2123-2129.
174. van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, van Dongen JJ. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97:3197-3204.
175. Nicolaou K, Smith A, Yue E. Chemistry and biology of natural and designed enediynes. Proc Natl Acad Sci USA 1993; 90:5881-5888.
176. Dedon PC, Goldberg IH. Free-radical mechanisms involved in the formation of sequence-dependent bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin, and calicheamicin. Chem Res Toxicol 1992; 5:311-332.
177. Gao Z, McAlister VC, Williams GM. Repopulation of liver endothelium by bone-marrow-derived cells. Lancet 2001; 357:932-933.
178. Takezawa RI, Watanabe Y, Akaike T. Direct evidence of macrophage differentiation from bone marrow cells in the liver: a possible origin of Kupffer cells. J Biochem 1995; 118: 1175-1183.
179. Durden DL, Salazar AM, Distasio JA. Kinetic analysis of hepatotoxicity associated with antineoplastic asparaginases. Cancer Res 1983; 43:1602-1605.
180. Villa P, Corada M, Bartosek I. L-asparaginase effects on inhibition of protein synthesis and lowering of the glutamine content in cultured rat hepatocytes. Toxicol Lett 1986; 32:235-241.
181. Land VJ, Sutow WW, Fernbach DJ, Lane DM, Williams TE. Toxicity of L-asparaginase in children with advanced leukemia. Cancer 1972; 30:339-347.
182. Pratt CB, Johnson WW. Duration and severity of fatty metamorphosis of liver following L-asparaginase therapy. Cancer 1971; 28:361-364.
183. Chim CS, Kwong YL, Chu YC, Chan CH, Chan YT, Liang R. Improved treatment outcome in adult acute lymphoblastic leukemia using the intensive German protocol, a preliminary report. Hematol Oncol 1997; 15:19-26.
184. Wiernik PH, Dutcher JP, Paietta E, Gucalp R, Markus S, Weinberg V, Azar C, Garl S, Benson L. Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: a non-anthracycline containing regimen. Leukemia 1993; 7:1236-1241.
185. Rizzari C, Valsecchi MG, Arico M, Conter V, Testi A, Barisone E, Casale F, Lo Nigro L, Rondelli R, Basso G, Santoro N, Masera G, Associazione Italiano Ematologia Oncologia P. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Miinster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study—a report from the Associazione Italiana Ematologia Oncologia Pediatrica. J Clin Oncol 2001; 19:1297-1303.
186. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Arkin S, Declerck L, Cohen HJ, Sallan SE. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97:1211-1218.
187. Flentje M, Weirich A, Potter R, Ludwig R. Hepatotoxicity in irradiated nephroblastoma patients during postoperative treatment according to SIOP9/GPOH. Radiother Oncol 1994; 31: 222-228.
188. Tornesello A, Piciacchia D, Mastrangelo S, Lasorella A, Mastrangelo R. Veno-occlusive disease of the liver in right-sided Wilms’ tumours. Eur J Cancer 1998; 34:1220-1223.
189. Ludwig R, Weirich A, Hofmann WJ, Waldherr R. Veno-occlusive disease as hepatotoxic side effect of the nephroblastoma SIOP-9 treatment protocol: Preliminary results of the German group. Med Pediatr Oncol 1992; 20:434.
190. Ortega JA, Donaldson SS, Ivy SP, Pappo A, Maurer HM. Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. Cancer 1997; 79:2435-2439.
191. Mushtaq I, Carachi R, Roy G, Azmy A. Childhood renal tumours with intravascular extension. Br J Urol 1996; 78:772-776.
192. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995; 31:1237-1248.
193. Ingold JA, Reed GB, Jr., Kaplan HS, Bagshaw MA. Radiation hepatitis. AJR 1965; 93:200-208.
194. Reed GB, Jr., Cox AJ, Jr. The human liver after radiation injury: a form of veno-occlusive disease. Am J Pathol 1966; 48:597-611.
195. Selzer G, Parker RGF. Senecio poisoning exhibiting as Chiari’s syndrome: a report on twelve cases. Am J Pathol 1950; 27:885-907.
196. McGinn CJ, Ten Haken RK, Ensminger WD, Walker S, Wang S, Lawrence TS. Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. J Clin Oncol 1998; 16:2246-2252.
197. Grinsky T, Benhamou E, Bourhis JH, Dhermain F, Guillot-Valls D, Ganansia V, Luboinski M, Perez A, Cosset J-M, Socie G, Baume D, Bouaouina N, Briot E, Beaudre A, Bridier A, Pico JL. Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies. J Clin Oncol 2000; 18:981-986.
198. Hopewell J, Withers HR. Proposition: long-term changes in irradiated tissues are due principally to vascular damage in the tissues. Med Phys 1998; 25:2265-2268.
199. Cicciarello R, d’Avella D, Gagliardi ME, Albiero F, Vega J, Angileri FF, D’Aquino A, Toma-sello F. Time-related ultrastructural changes in an experimental model of whole brain irradiation. Neurosurgery 1996; 38:772-779; discussion 779-780.
200. Rezvani M, Hopewell JW, Robbins ME. Initiation of non-neoplastic late effects: the role of endothelium and connective tissue. Stem Cells 1995; 13:248-256.
201. Hopewell JW, Calvo W, Jaenke R, Reinhold HS, Robbins ME, Whitehouse EM. Microvasculature and radiation damage. Recent Results Cancer Res 1993; 130:1-16.
202. Jaenke RS, Robbins ME, Bywaters T, Whitehouse E, Rezvani M, Hopewell JW. Capillary endothelium. Target site of renal radiation injury. Lab Invest 1993; 68:396-405.
203. Reinhold HS. The influence of radiation on blood vessels and circulation. Chapter II. Cell viability of the vessel wall. Curr Topics Radiat Res Q 1974; 10:9-28.
204. Langley RE, Bump EA, Quartuccio SG, Medeiros D, Braunhut SJ. Radiation-induced apoptosis in microvascular endothelial cells. Br J Cancer 1997; 75:666-672.
205. Pena LA, Fuks Z, Kolesnick RN. Radiation-induced apoptosis of endothelial cells in the murine central nervous system: Protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res 2000; 60:321-327.
206. Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, Haimovitz-Friedman A, Cordon-Cardo C, Kolesnick R. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001; 293:293-297.
207. Morales A, Miranda M, Sanchez-Reyes A, Biete A, Fernandez-Checa JC. Oxidative damage of mitochondrial and nuclear DNA induced by ionizing radiation in human hepatoblastoma cells. Int J Radiat Oncol Biol Phys 1998; 42:191-203.
208. Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Non-alcoholic steatohepatitis. Lancet 1999; 354:1299-1300.
209. Van Hoof M, Rahier J, Horsmans Y. Tamoxifen-induced steatohepatitis [letter]. Ann Intern Med 1996; 124:855-856.
210. Pratt DS, Knox TA, Erban J. Tamoxifen-induced steatohepatitis [letter]. Ann Intern Med 1995; 123:236.
211. Oien KA, Moffat D, Curry GW, Dickson J, Habeshaw T, Mills PR, MacSween RN. Cirrhosis with steatohepatitis after adjuvant tamoxifen [letter]. Lancet 1999; 353:36-37.
212. Cortez Pinto H, Baptista A, Camilo ME, Bruno de Costa E, Valente A, Carneiro de Moura M. Tamoxifen-associated steatohepatitis-report of three cases. J Hepatol 1995; 23:95-97.
213. Murata Y, Ogawa Y, Saibara T, Nishioka A, Fujiwara Y, Fukumoto M, Inomota T, Enzan H, Onishi S, Yoshida S. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Reports 2000; 7:1299-1304.
214. Loomus GN, Aneja P, Bota RA. A case of peliosis hepatis in association with tamoxifen therapy. Am J Clin Pathol 1983; 80:881-883.
215. Storen EC, Hay JE, Kaur J, Zahasky K, Hartmann L. Tamoxifen-induced submassive hepatic necrosis. Cancer J 2000; 6:58-60.
216. Moffat DF, Oien KA, Dickson J, Habeshaw T, McLellan DR. Hepatocellular carcinoma after long-term tamoxifen therapy. Ann Oncol 2000; 11:1195-1196.
217. Law CH, Tandan VR. The association between tamoxifen and the development of hepatocellular carcinoma: case report and literature review. Can J Surg 1999; 42:211-214.
218. Wilking N, Isaksson E, von Schoultz E. Tamoxifen and secondary tumours: an update. Drug Safety 1997; 16:104-117.
219. Dragan YP, Fahey S, Street K, Vaughan J, Jordan VC, Pitot HC. Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Res Treat 1994; 31:11-25.
220. Carthew P, Martin EA, White IN, De Matteis F, Edwards RE, Dorman BM, Heydon RT, Smith LL. Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: Promotion by phenobarbital. Cancer Res 1995; 55:544-547.
221. Martin EA, Rich KJ, White IN, Woods KL, Powles TJ, Smith LL. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 1995; 16: 1651-1654.
222. Rabe T, Feldmann K, Heinemann L, Runnebaum B. Cyproterone acetate: is it hepato- or genotoxic? Drug Safety 1996; 14:25-38.
223. Hinkel A, Berges RR, Pannek J, Schulze H, Senge T. Cyproterone acetate in the treatment of advanced prostatic cancer: retrospective analysis of liver toxicity in the long-term followup of 89 patients. Eur Urol 1996; 30:464-470.
224. Anonymous. Hepatic reactions with cyproterone acetate (Cyprostat, Androcur). Curr Problems Pharmacovigilance 1995; 21:1.
225. Garty BZ, Dinari G, Gellvan A, Kauli R. Cirrhosis in a child with hypothalamic syndrome and central precocious puberty treated with cyproterone acetate. Eur J Pediatr 1999; 158: 367-370.
226. Werner S, Topinka J, Kunz S, Beckurts T, Heidecke CD, Schwarz LR, Wolff T. Studies on the formation of hepatic DNA adducts by the antiandrogenic and gestagenic drug, cyproter-one acetate: 1. adduct levels in various species including man and 2. persistence and accumulation in the rat. Adv Exp Med Biol 1996; 387:253-257.
227. Schwarz LR, Werner S, Topinka J, Andrae U, Neumann I, Wolff T. The liver as origin and target of reactive intermediates exemplified by the progesterone derivative, cyproterone acetate. Adv Exp Med Biol 1996; 387:243-251.
228. Oosterlinck W, Casselman J, Mattelaer J, Van Velthoven R, Kurjatkin O, Schulman C. Tolerability and safety of flutamide in monotherapy, with orchiectomy or with LHRH-a in advanced prostate cancer patients: a Belgian multicenter study of 905 patients. Eur Urol 1996; 30:458-463.
229. Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol 1996; 155:209-212.
230. Berson A, Wolf C, Chachaty C, Fisch C, Fau D, Loeper J, Gauthier JC, Beaune P, Pompon D, Maurel P, Pessayre D. Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochrome P-450, including forms belonging to the 3A and 1A subfamilies. J Pharmacol Exp Ther 1983; 265:366-372.
231. Fau D, Eugene D, Berson A, Letteron P, Fromenty B, Fisch C, Pessayre D. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 1994; 269:954-962.
232. De Vita VT, Carbone PP, Owens AH, Jr., Gold GL, Krant MJ, Edmonson J. Clinical trials with 1,3-£’A(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res 1965; 25:1876-1881.
233. Phillips GL, Fay JW, Herzig GP, Herzig RH, Weiner RS, Wolff SN, Lazarus HM, Karanes C, Ross WE, Kramer BS. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC: 4366650 and cryopreserved autologous marrow transplantation for refractory cancer: a phase I-II study. Cancer 1983; 52:1792-1802.
234. Hoth D, Woolley P, Green D, Macdonald J, Schein P. Phase I studies on chlorozotocin. Clin Pharmacol Ther 1978; 23:712-722.
235. Johnson RO, Metter G, Wilson W, Hill G, Krementz E. Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group. Cancer Treat Rep 1976; 60:183-187.
236. Chard RL, Jr., Krivit W, Bleyer WA, Hammond D. Phase II study of VP-16-213 in childhood malignant disease: a Children’s Cancer Study Group Report. Cancer Treat Rep 1979; 63: 1755-1759.
237. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12:1535-1540.
238. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12:1821-1826.
239. Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J, et al. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5:543-547.
240. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86:1530-1533.
241. Hoogstraten B, Gottlieb JA, Caoili E, Tucker WG, Talley RW, Haut A. CCNU (1-(2-chloro-ethyl)-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer: Phase II study. Cancer 1973; 32:38-43.
242. Paciucci PA, Ohnuma T, Cuttner J, Silver RT, Holland JF. Mitoxantrone in patients with acute leukemia in relapse. Cancer Res 1983; 43:3919-3922.
243. Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng YM, Baier M, Plezia P. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993; 11:2002-2009.
244. Feenstra J, Vermeer RJ, Stricker BH. Fatal hepatic coma attributed to paclitaxel [letter]. J Natl Cancer Inst 1997; 89:582-584.
245. Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozo-tocin in 52 patients. Ann Intern Med 1973; 79:108-118.
246. Coe JE, Ishak KG, Ross MJ. Estrogen-induced hepatic toxicity and hepatic cancer: differences between two closely related hamster species. Liver 1998; 18:343-351.
247. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.